Streetbeat News

Price Targets

PEN

Truist Securities analyst David Rescott has reaffirmed a Buy rating on Penumbra (NYSE:PEN) and increased the price target from $265 to $295. This adjustment reflects a positive outlook on the company's stock, suggesting potential upside from the previous target.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 3:04 pm

PRCT

Truist Securities analyst Richard Newitter has maintained a Buy rating on PROCEPT BioRobotics (NASDAQ:PRCT) and increased the price target from $48 to $50.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 3:02 pm

EW

Analysts have provided diverse perspectives on Edwards Lifesciences (NYSE:EW), with 14 ratings in the last three months. The average 12-month price target is now $78.5, down 11.62% from the previous $88.82. Analysts have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Edwards Lifesciences, known for its medical devices for structural heart disease, has shown a revenue growth of 12.27% and strong financial health with high net margin and ROE. However, its revenue growth lags behind industry peers.

Portfolio Pulse from Benzinga Insights

December 22, 2023 | 3:01 pm

ROST

Ross Stores (NASDAQ:ROST) received mixed ratings from 8 financial analysts, with an average 12-month price target of $138.12, up from $132.60. Analysts from firms like Wells Fargo, BMO Capital, Morgan Stanley, Telsey Advisory Group, Evercore ISI Group, and Gordon Haskett have raised their price targets, reflecting a positive outlook on the company's performance. Ross Stores has shown solid revenue growth, exceptional net margin, and impressive ROE and ROA, with a prudent approach to debt management.

Portfolio Pulse from Benzinga Insights

December 22, 2023 | 3:01 pm

KIDS

Truist Securities analyst Richard Newitter has maintained a Buy rating on OrthoPediatrics (NASDAQ:KIDS) and increased the price target from $35 to $39.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 3:01 pm

VSCO

Victoria's Secret (NYSE:VSCO) has received mixed analyst ratings over the past three months, with the majority being indifferent. The average 12-month price target for VSCO has increased by 17.35% to $23.00, with a high estimate of $29.00 and a low of $16.00. Analysts from firms like Wells Fargo, Morgan Stanley, Telsey Advisory Group, BMO Capital, and Evercore ISI Group have updated their ratings and price targets, reflecting their views on the company's market performance. Victoria's Secret's financial performance shows a market cap below industry average, a revenue decline of -4.02%, low net margin, ROE, and ROA, and a high debt-to-equity ratio, indicating potential challenges ahead.

Portfolio Pulse from Benzinga Insights

December 22, 2023 | 3:01 pm

KMX

Analysts have mixed views on CarMax (NYSE:KMX), with 14 ratings ranging from bullish to bearish. The average 12-month price target is $79.93, down from $82.30. Actions taken by analysts include maintaining, raising, or lowering ratings and price targets. CarMax's financial performance shows a negative revenue trend but strong profitability indicators like net margin and ROE. The company is the largest used-vehicle retailer in the U.S. with plans to increase market share.

Portfolio Pulse from Benzinga Insights

December 22, 2023 | 3:00 pm

NVRO

Truist Securities analyst Richard Newitter has maintained a Hold rating on Nevro Corp (NYSE:NVRO) and increased the price target from $22 to $23.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 2:59 pm

NKE

Truist Securities analyst Beth Reed has maintained a Hold rating on Nike (NYSE:NKE) and reduced the price target from $108 to $107.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 2:58 pm

MDT

Truist Securities analyst Richard Newitter has maintained a Hold rating on Medtronic (NYSE:MDT) and increased the price target from $84 to $87.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 2:56 pm